FCGR2A and breast cancer: For instance, in patients with breast cancer who are human epidermal growth factor receptor 2 (HER2) positive, Trastuzumab effectively suppresses tumor growth by binding to FcγRIIIa, thereby activating natural killer cells and macrophages and enhancing the ADCC response.[37] A deeper understanding of FcγR biology may pave the way for innovative strategies to modulate immune responses and enhance therapeutic efficacy in diverse clinical scenarios.